Halozyme Therapeutics HALO Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax
Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax at other companies
Other financials
Where this comes from
Reported directly by Halozyme Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax.
The official record: Halozyme Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about Halozyme Therapeutics's debt securities, available-for-sale, accumulated gross unrealized loss, before tax.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Halozyme Therapeutics's debt securities, available-for-sale, accumulated gross unrealized loss, before tax?
- Halozyme Therapeutics (HALO) reported debt securities, available-for-sale, accumulated gross unrealized loss, before tax of $5K in Q1 2026.
- How has Halozyme Therapeutics's debt securities, available-for-sale, accumulated gross unrealized loss, before tax changed year-over-year?
- Halozyme Therapeutics's debt securities, available-for-sale, accumulated gross unrealized loss, before tax decreased by 98.9% year-over-year, from $462K to $5K.
- What is the long-term trend for Halozyme Therapeutics's debt securities, available-for-sale, accumulated gross unrealized loss, before tax?
- Over 5 years (2020 to 2025), Halozyme Therapeutics's debt securities, available-for-sale, accumulated gross unrealized loss, before tax has grown at a -24.2% compound annual growth rate (CAGR), from $8K to $2K.